Inspire Medical Systems’ chief operating officer Philip Ebeling will leave effective Aug. 9, the company said Monday.
Ebeling joined Inspire, which sells an implantable nerve stimulator to treat obstructive sleep apnea, in 2020 and led a team that spanned manufacturing, quality systems, regulatory affairs and clinical affairs. The company grew in Ebeling’s time at Inspire, going from fewer than 350 employees at the end of 2020 to more than 1,000 at the end of 2023.
Now, Ebeling has told Inspire he will resign to become president and CEO of “a private medical device company operating in the cardiology space.”
Inspire said the resignation is not due to a dispute or disagreement with the company or its management regarding any matter relating to its operations, policies or practices. The company has begun looking for a replacement chief operating officer with the help of an executive search firm.
News of the resignation coincided with Inspire’s appointment of Melissa Mann as chief people officer. Mann replaced Steven Jandrich, who retired in May. Mann has joined Inspire from UnitedHealth Group.
CEO Tim Herbert said in a statement that the company will leverage Mann’s “vast experience in human capital management as we continue to grow and scale our organization.”
Inspire shared news of the leadership changes days after disclosing the receipt of a CE mark under the European Union’s Medical Device Regulation. The company received a CE mark under the old EU device directive in 2010.
Under the new CE mark, Inspire patients in the EU may undergo full-body MRI scans in the 1.5T MRI environment. The CE mark covers a device that has leads with silicone insulation.